BOTHELL, Wash.--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company discovering new drug therapies for eye diseases, today announced that data from a preclinical study in retinopathy of prematurity (ROP) will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 27 through May 1 in Fort Lauderdale, Florida. The data will be presented by researchers from Children’s Hospital Boston.
